MX2019005230A - Preparacion de complejo farmaceutica que comprende amlodipina, losartan y rosuvastatina. - Google Patents

Preparacion de complejo farmaceutica que comprende amlodipina, losartan y rosuvastatina.

Info

Publication number
MX2019005230A
MX2019005230A MX2019005230A MX2019005230A MX2019005230A MX 2019005230 A MX2019005230 A MX 2019005230A MX 2019005230 A MX2019005230 A MX 2019005230A MX 2019005230 A MX2019005230 A MX 2019005230A MX 2019005230 A MX2019005230 A MX 2019005230A
Authority
MX
Mexico
Prior art keywords
losartan
rosuvastatin
complex preparation
amlodipine
active ingredients
Prior art date
Application number
MX2019005230A
Other languages
English (en)
Inventor
Il Kim Yong
Hyun Park Jae
Soo Woo Jong
Taek Im Ho
Jun Cho Hyuk
Ee Lim Sol
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62146632&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2019005230(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of MX2019005230A publication Critical patent/MX2019005230A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a una preparación de complejo farmacéutica que incluye amlodipina, losartán y rosuvastatina como ingredientes activos. La preparación de complejo farmacéutica de la presente invención que incluye amlodipina, losartán y rosuvastatina como ingredientes activos presenta excelentes características de disolución de todos los ingredientes activos, y también tiene una estabilidad de preparación mejorada. Por lo tanto, la preparación de complejo de la presente invención se puede usar como un agente profiláctico o terapéutico para enfermedades cardiovasculares, que ha asegurado la estabilidad de la calidad incluso cuando se almacena durante un largo período de tiempo.
MX2019005230A 2016-11-15 2017-11-10 Preparacion de complejo farmaceutica que comprende amlodipina, losartan y rosuvastatina. MX2019005230A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020160152077 2016-11-15
PCT/KR2017/012703 WO2018093096A2 (en) 2016-11-15 2017-11-10 Pharmaceutical complex preparation comprising amlodipine, losartan and rosuvastatin

Publications (1)

Publication Number Publication Date
MX2019005230A true MX2019005230A (es) 2019-08-14

Family

ID=62146632

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019005230A MX2019005230A (es) 2016-11-15 2017-11-10 Preparacion de complejo farmaceutica que comprende amlodipina, losartan y rosuvastatina.

Country Status (11)

Country Link
CO (1) CO2019004796A2 (es)
CR (1) CR20190265A (es)
DO (1) DOP2019000092A (es)
EA (1) EA201991190A1 (es)
EC (1) ECSP19040732A (es)
MX (1) MX2019005230A (es)
NI (1) NI201900048A (es)
PH (1) PH12019500779A1 (es)
SG (1) SG11201903132YA (es)
WO (1) WO2018093096A2 (es)
ZA (1) ZA201902720B (es)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100029654A1 (en) * 2006-03-23 2010-02-04 Mount Sinai School Of Medicine Cardiovascular compositions and use of the same for the treatment of alzheimer's disease
KR101298788B1 (ko) * 2011-03-15 2013-08-22 보령제약 주식회사 안정성이 개선된 복합제제
MX358211B (es) * 2012-07-23 2018-08-10 Landsteiner Scient S A De C V Una composición farmacéutica de liberación comprendiendo hidroclorotiazida, losartán y basilato de amlodipino.
KR101910901B1 (ko) * 2013-11-29 2018-10-24 한미약품 주식회사 암로디핀, 로자탄 및 로수바스타틴을 포함하는 약제학적 복합 제제
KR102369607B1 (ko) * 2014-09-30 2022-03-03 한미약품 주식회사 암로디핀 및 로잘탄을 포함하는 고형 약제학적 조성물

Also Published As

Publication number Publication date
EA201991190A1 (ru) 2019-10-31
ZA201902720B (en) 2020-08-26
WO2018093096A2 (en) 2018-05-24
NI201900048A (es) 2019-10-11
ECSP19040732A (es) 2019-07-31
DOP2019000092A (es) 2019-09-30
CO2019004796A2 (es) 2019-05-21
SG11201903132YA (en) 2019-05-30
WO2018093096A3 (en) 2018-07-26
PH12019500779A1 (en) 2019-07-29
CR20190265A (es) 2019-08-22

Similar Documents

Publication Publication Date Title
PH12017501956A1 (en) Compositions of obeticholic acid and methods of use
MX2016014320A (es) Composiciones de suspension de liberacion prolongada.
PH12016502248A1 (en) Adenoassociated virus vectors for the treatment of lysosomal storage disorders
MX2019015744A (es) Composiciones farmaceuticas.
PH12016501122A1 (en) Delayed release compositions of linaclotide
PH12019500778A1 (en) Pharmaceutical complex formulation comprising amlodipine, losartan and chlorthalidone
NZ725399A (en) Macrocylic pyrimidine derivatives
MX2019012803A (es) Nuevos derivados de pirazol biciclicos.
EA201791009A1 (ru) Композиции, содержащие циклоспорин
PH12016502544B1 (en) Pharmaceutical preparation containing entecavir as active ingredient, and preparation method therefor
PH12017500536A1 (en) Solid pharmaceutical composition comprising amlodipine and losartan
PH12019500779A1 (en) Pharmaceutical complex preparation comprising amlodipine, losartan and rosuvastatin
MA39009A (fr) Compositions pharmaceutiques comprenant un agent actif
GR20150100035A (el) Φαρμακευτικο σκευασμα περιεχον απρεπιταντη και μεθοδος παρασκευης αυτου
PH12016502527B1 (en) Stabilized desmopressin
EA201891848A1 (ru) Фармацевтическая композиция для применения в лечении фиброза
MY194591A (en) Pharmaceutical combination formulation
GB2541348A (en) Clopidogrel for use in the treatment of benign prostatic hyperplasia